3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 2
3
Phase NA
1
Phase 4
1
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
11
Thoracic
7
Gastrointestinal
6
CNS
4
Sarcoma
3
Other hematologic neoplasm
3
Head & Neck
3
Gynecologic
3
Dermatologic
3
Genitourinary
2
Tumor-Agnostic
1
Myeloid
1
Lymphoid
1
Conditions
Melanoma
3
Skin Neoplasms
1
Recurrence
1
Neoplasms
1
Interventions
Dacarbazine
27
Nivolumab
26
pembrolizumab
22
Ipilimumab
20
3-ingenyl angelate
11
Interferon-alpha
10
Imiquimod
10
Temozolomide
9
trametinib
8
Vemurafenib
8
Photochemotherapy
8
Aminolevulinic Acid
8
methyl 5-aminolevulinate
7
dabrafenib
7
cemiplimab
7
aldesleukin
7
Introns
7
Surgical Procedures, Operative
6
Radiotherapy
6
Interferon alpha-2
6
Fluorouracil
6
Paclitaxel
5
Melphalan
5
Interleukin-2
5
Cisplatin
5
Chemotherapy, Adjuvant
5
talimogene laherparepvec
4
binimetinib
4
Specimen Handling
4
Opdualag
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Sodium Chloride
×
Dermatologic
×
Clear all
NCT05899465
2025-03-18
PRIME
University of Aarhus
Phase 3
Recruiting
1,204 enrolled
NCT03233828
2024-07-24
IL-2
Nova Scotia Health Authority
Phase 3
Terminated
1 enrolled
3 charts
NCT00518895
2011-11-07
AGENDA
Genta Incorporated
Phase 3
Completed
300 enrolled